tbuckley/cabot-search huggingface dataset:
Abstract P5-13-21: The European initiative in breast cancer (ECIBC) - A program to reduce disparities in cancer care by accreditation of all breast centers in Europe
Authors: RE Mansel
Journal: Cancer Research (2019)

Abstract In order to reduce disparities in breast cancer services in Europe, the European Parliament passed resolutions in 2003 and 2006 calling for all women with breast cancer in Europe to be treated by a multidisciplinary team and called on Member States to establish a network of Certified multidisciplinary breast centres. In the light of these resolutions the European Commission has tasked the Joint Research Centre (JRC) based in Ispra in Italy to set a programme of work from 2014-2020 to update the European Screening Guidelines and produce standards for an accreditation programme for all European Member States. The methodology is evidence based and the Ibero American Cochrane group has been recruited to examine the evidence for the key questions concerning quality indicators. The whole pathway for breast cancer treatment is being explored from screening to follow up/survivorship, and only indicators supported by evidence are accepted. Indicators have to be relevant, measurable and feasible and currently 50 indicators have been approved using the Delphi system. Many currently used indicators have failed the test of usability due to lack of precision in measurement (eg cosmetic outcomes, margin assessment), or lack of clear definitions (eg counselling,breast care nurse roles, waiting times, MDT working). A further problem is the different resources applied to breast services across the wide range of economies in European countries (Western v Eastern Europe), which affects the availability of expensive therapies. The Indicators will form the basis of the accreditation program which will be published in 2019. The detailed evidence for each indicator will be presented in the poster together with the feedback from the 30+European countries involved. A pilot of the accreditation program will take place in 2019 to test the feasibility of the audit process in a variety of breast clinic settings. This project is the most comprehensive attempt to date to produce a robust measurement of breast centers performance based on evidence, and might have global applicability. Citation Format: Mansel RE. The European initiative in breast cancer (ECIBC) - A program to reduce disparities in cancer care by accreditation of all breast centers in Europe [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-13-21.
Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma
Authors: Giulia Bartalucci, Elisa Coviello, Fabio Guolo, Paola Minetto, Massimiliano Gambella, Giulia Rivoli, Daniela Guardo, Filippo Ballerini, Maurizio Miglino, Alberto Fabbri, Roberto M Lemoli, Monica Bocchia, Marco Gobbi
Journal: Blood (2017)
Respiratory findings in fish processing workers
Authors: E.Neil Schachter, Eugenija Žuškin, Jadranka Mustajbegović
Journal: American Journal of Respiratory and Critical Care Medicine (2009)

The preset study was undertaken to investigate respiratory symptoms and lung function abnormalities in 98 female workers employed in a fish processing industry. The mean duration of employment of these workers was 20 years. This study demonstrates a high prevalence of respiratory abnormalities related to workplace exposure in these group of female fish processing workers.
Abstract P1-17-06: Breast cancer in elderly women: Ageism or primum non nocere?
Authors: M Muzaffar, N Vohra, J Wong
Journal: Cancer Research (2019)

Abstract Background: The risk of breast cancer increases with advancing age. Routine use of screening mammogram in women after 75yrs and its impact on overall survival is controversial. Studies have also found that elderly breast cancer patients are underrepresented among clinical trials and a tendency for undertreatment may result in inferior outcome. Method and Material:Female patients with breast cancer who were 75 years or older and diagnosed from 2000-2015 were identified from Surveillance, Epidemiology, and End Results (SEER) 18 database. We excluded patients with unknown stage and race. We performed multivariate and survival analysis using JMP pro 13. Results: 186,682 women with breast cancer of ≥ 75 yrs. were identified from the SEER. 167,802 patients met the inclusion criteria. Mean age was 81.27 years (CI 95% 81.25-81.30). Most of the patients were white (88%), and had Stage I/II (83%) breast cancer.78% of patients had estrogen receptor positive cancer, while 66% had grade 1/2 disease. The 5-year overall survival was 74% for Stage I,60% for Stage II,38% for stage III and 11% for Stage IV cancer(p&amp;lt;0.0001). The disease specific survival (DSS)for stage I (96%), Stage II (88%), Stage III (64%), and Stage IV (23%).Out of the patients who were deceased at the time of analysis only 24% of deaths were attributed to this cancer. Cox proportional hazards regression model of overall survival [Table:1] Cox proportional hazards regression model of overall survivalVariableHazard ratio( 95% CI)p value75—79 80-84 85+1 1.22 1.7&amp;lt;0.0001Race White Black Others1 1.14 0.95&amp;lt;0.001ER Positive Negative unknown1 1.19 1.2&amp;lt;0.001Stage I Stage II Stage III Stage IV1 1.17 1.66 3.7&amp;lt;0.001 Conclusion: Early breast cancer continues to be the most common presentation for patients ≥75 yrs. of age. Historical prognostic factors of breast cancer like race, hormone receptor status, stage and grade continue to impact cancer outcome among elderly patients. Only 24% of deaths among the deceased were attributed to this breast cancer highlighting the concern for over diagnosis. Nonetheless once diagnoses is established a multidisciplinary comprehensive geriatric assessment should be the cornerstone of the management. Citation Format: Muzaffar M, Vohra N, Wong J. Breast cancer in elderly women: Ageism or primum non nocere? [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-17-06.
Abstract A29: Omics profile of two immortalized Brazilian glioblastoma cell cultures
Authors: Adriana Cruvinel-Carloni, Renato José da Silva-Oliveira, Viviane Aline Oliveira-Silva, Marcela Nunes Rosa, Lucas Tadeu Bidinotto, Gustavo Noriz Berdinarelli, Raul Torrieri, Adriane Feijó Evangelista, Olga Catarina Martinho, Vera Mónica Gonçalves, Carlos Clara, Gisele Caravina de Almeida, Rui Manuel Reis
Journal: Clinical Cancer Research (2018)

Abstract Background: Glioblastomas are the most frequent and deadly brain tumors. Genomic alterations, as well as its high heterogeneity, are important features of these tumors. Despite the advances in the biology of these tumors, it is essential to develop models, such as primary tumor cell lines, that better mimic their genomic diversity and therapeutic behavior. We aimed to characterize the molecular profile of two (HCB2 and HCB151) established immortalized glioblastoma cell lines. Methods: Immortalized glioblastoma cell lines, HCB2 and HCB151, were established from Barretos Cancer Hospital patients diagnosed with glioblastoma. The cells were cultured with DMEM+10%BFS+1%PS and molecularly characterized, using arrayCGH, next-generation sequencing (Ion Torrent) and validated by Sanger sequencing, miRNA expression and CNV using the NanoString platform, and BD Lyoplate™ Human Cell Surface Marker Screening Panel using Accuri™ C6 flow cytometer. The tumorigenic capacity was further determined in vivo by the chicken chorioallantoic membrane (CAM) assay, and its response to temozolomide-based chemotherapy was done by MTS. Results: The aCGH analysis showed that the most frequent events was the gain of chromosome 7 and loss of chromosomes 10, 13, and 17p. HCB2 exhibited mutations in the TERT gene, while HCB151 showed mutations in the TP53, PTEN, LZTR1, and TERT genes. The immortalized cultures present an unique miRNA profile. The CAM assay showed that HCB2 and HCB151 were able to form vascularized tumors, with HCB151 more aggressive than HCB2. In addition, both HCB2 (IC50&amp;gt;1000 µM) and HCB151 (IC50=783 µM) showed resistance to TMZ when compared to commercial glioblastomas cell lines (23-441 µM). Conclusion: The present findings showed that the immortalized glioblastoma cell lines showed classic genomic features of glioblastomas and exhibited a similar biologic behavior, suggesting that these cell lines are a good model for glioblastoma preclinical studies. Citation Format: Adriana Cruvinel-Carloni, Renato José da Silva-Oliveira, Viviane Aline Oliveira-Silva, Marcela Nunes Rosa, Lucas Tadeu Bidinotto, Gustavo Noriz Berdinarelli, Raul Torrieri, Adriane Feijó Evangelista, Olga Catarina Martinho, Vera Mónica Gonçalves, Carlos Clara, Gisele Caravina de Almeida, Rui Manuel Reis. Omics profile of two immortalized Brazilian glioblastoma cell cultures [abstract]. In: Proceedings of the AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; São Paulo, Brazil. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(1_Suppl):Abstract nr A29.
The emotional cost of complications
Authors: Luke Austen
Journal: BMJ (2014)

Many public figures and celebrities write autobiographies billed as confessions, but the memoirs of the neurosurgeon Henry Marsh are strikingly candid and unreserved. Throughout Do No Harm: Stories of Life, Death and Brain Surgery Marsh reflects on harrowing moments in his career, always with clarity and honesty, cross examining his past actions in a manner suggestive of someone who remains deeply troubled by these events. And no wonder. The results of neurosurgery gone wrong are shown to be truly horrifying and desperately sad. The image of a mother “pushing her mute and disfigured daughter in her wheelchair” or of a …
Abstract SY30-03: First impressions of the multiple myeloma genome
Authors: Todd R. Golub
Journal: Cancer Research (2010)

Abstract Multiple myeloma is a malignancy of mature B-lymphoid cells whose pathogenesis remains obscure. To address this, we undertook a large-scale effort to characterize the genomes of multiple myleoma tumor samples and their matched normal DNAs. Funded by the Multiple Myeloma Research Foundation, this sequencing effort is one of the largest cancer genome sequencing projects completed to date, representing 29 patients (22 whole genomes and 17 whole exomes) sequenced to an average of 30X coverage. Improvements in mutation-calling algorithms yielded a mutation rate of ~ 10-6, with a mutation validation rate of 97%, indicating that the false-positive rate of mutations in this dataset is extremely low. Highlights of novel and biologically important findings from this dataset will be presented, and include: 1) mutations in the transcription factor IRF4; 2) mutations in histone methyltransferases; 3) mutations in genes involved in protein translation; 4) mutations in genes involved in blood coagulation; and 5) an activating mutation in BRAF, for which small-molecule inhibitors are in clinical development. These results suggest that sequencing of the multiple myeloma genome will provide new insights into the pathogenesis of multiple myeloma, and moreover suggest that while mutations in particular genes may be rare, they may result in the aberrant activity of common pathways. This in turn suggests that the sequencing of large numbers of cancer genomes may be required to develop a full understanding of the biological consequences of somatic mutations. Citation Format: Todd R. Golub. First impressions of the multiple myeloma genome [abstract]. In: Proceedings of the AACR 101st Annual Meeting 2010; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr SY30-03
Abstract P6-09-07: Expression of miR-106b in circulating tumor cells is associated with EMT and prognosis in metastatic breast cancer patients
Authors: W Tan, G Liang, X Xie, L Tan, AJ Sanders, Z Liu, Y Ling, W Zhong, WG Jiang, C Gong
Journal: Cancer Research (2019)

Abstract # Co-first author: W.T., G.L., X.X. * Co-Correspondence: C.G. and W.G.J. Abstract Background: Circulating tumor cells (CTCs) display changes in epithelial-mesenchymal transition (EMT) markers and miRNAs regulate EMT in breast cancer cells. The association between EMT characteristics and miRNA expression in CTCs of metastatic breast cancer (MBC) patients and their clinical implications remain unknown. Methods: CTC-specific miRNAs were screened based on comparison of the miRNA profile between CTC and primary tumor. RT-PCR was used to quantity the expression levels of EMT makers and miRNA candidates. We enrolled 219 MBC patients with CTCs ≥ 5/7.5mL blood from 2 cohorts and CTCs were detected and enriched by CellSearch. Overall survival (OS) and radiological response were analyzed. CTCs were divided into epithelial- (E-CTCs) and mesenchymal-like CTC (M-CTCs) phenotypes based on a cut-off value derived from suspended breast cancer cells recovered from PBMCs. Results: MiR-106b displayed upregulation in CTCs, with a higher level in M-CTCs than E-CTCs. Patients with E-CTCs showed better OS than those with M-CTCs (HR 1.77, 95% CI 1.14-2.78, P =0.012). CTCs from chemo-resistant MBC patients exhibited higher miR-106b. CTC-specific miR-106b was negatively associated with therapy response and OS (HR 1.73, 95% CI 1.06-2.84, P = 0.029). Conclusions: CTC-specific miR-106b was associated with EMT phenotypes of CTCs and may predict prognosis in MBC patients. Citation Format: Tan W, Liang G, Xie X, Tan L, Sanders AJ, Liu Z, Ling Y, Zhong W, Jiang WG, Gong C. Expression of miR-106b in circulating tumor cells is associated with EMT and prognosis in metastatic breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-09-07.
A non-epistemic, non-pictorial, internal, material visual field
Authors: Edmond Wright
Journal: Behavioral and Brain Sciences (2001)

The authors O'Regan &amp; Noë (O&amp;N) have ignored the case for the visual field as being non-epistemic evidence internal to the brain, having no pictorial similarity to the external input, and being material in ontological status. They are also not aware of the case for the evolutionary advantage of learning as the perceptual refashioning of such non-epistemic sensory evidence via motivated feedback in sensorimotor activity.
Methionine Adenosyltransferase α1 Is Targeted to the Mitochondrial Matrix and Interacts with Cytochrome P450 2E1 to Lower Its Expression
Authors: Ben Murray, Hui Peng, Lucia Barbier‐Torres, Aaron E. Robinson, Tony W. H. Li, Wei Fan, Maria Lauda Tomasi, Roberta A. Gottlieb, Jenny Van Eyk, Zhimin Lu, Maria L. Martínez‐Chantar, Suthat Liangpunsakul, Nicholas J. Skill, José M. Mato, Shelly C. Lu
Journal: Hepatology (2019)

Methionine adenosyltransferase α1 (MATα1, encoded by MAT1A ) is responsible for hepatic biosynthesis of S ‐adenosyl methionine, the principal methyl donor. MATα1 also act as a transcriptional cofactor by interacting and influencing the activity of several transcription factors. Mat1a knockout (KO) mice have increased levels of cytochrome P450 2E1 (CYP2E1), but the underlying mechanisms are unknown. The aims of the current study were to identify binding partners of MATα1 and elucidate how MATα1 regulates CYP2E1 expression. We identified binding partners of MATα1 by coimmunoprecipitation (co‐IP) and mass spectrometry. Interacting proteins were confirmed using co‐IP using recombinant proteins, liver lysates, and mitochondria. Alcoholic liver disease (ALD) samples were used to confirm relevance of our findings. We found that MATα1 negatively regulates CYP2E1 at mRNA and protein levels, with the latter being the dominant mechanism. MATα1 interacts with many proteins but with a predominance of mitochondrial proteins including CYP2E1. We found that MATα1 is present in the mitochondrial matrix of hepatocytes using immunogold electron microscopy. Mat1a KO hepatocytes had reduced mitochondrial membrane potential and higher mitochondrial reactive oxygen species, both of which were normalized when MAT1A was overexpressed. In addition, KO hepatocytes were sensitized to ethanol and tumor necrosis factor α–induced mitochondrial dysfunction. Interaction of MATα1 with CYP2E1 was direct, and this facilitated CYP2E1 methylation at R379, leading to its degradation through the proteasomal pathway. Mat1a KO livers have a reduced methylated/total CYP2E1 ratio. MATα1’s influence on mitochondrial function is largely mediated by its effect on CYP2E1 expression. Patients with ALD have reduced MATα1 levels and a decrease in methylated/total CYP2E1 ratio. Conclusion: Our findings highlight a critical role of MATα1 in regulating mitochondrial function by suppressing CYP2E1 expression at multiple levels.
Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation
Authors: Giada Rotunno, Carmela Mannarelli, Giada Brogi, Annalisa Pacilli, Francesca Gesullo, Francesco Mannelli, Sara Fiaccabrino, Benedetta Sordi, Chiara Paoli, Ilaria Marone, Elisa Rumi, Rossella Manfredini, Giovanni Barosi, Mario Cazzola, Alessandro M. Vannucchi, Paola Guglielmelli
Journal: Blood (2019)
Abstract P3-12-16: Five year outcomes of a prospective study of proton radiotherapy for breast cancer regional nodal irradiation
Authors: JA Bradley, R Dagan, X Liang, MW Ho, M Rutenberg, R Mailhot, C Morris, NP Mendenhall
Journal: Cancer Research (2019)

Abstract Purpose: Through improved nodal coverage and decreased dose to the heart and lung, proton therapy (PT) may improve the therapeutic ratio for treatment of breast cancer requiring regional nodal irradiation (RNI). The purpose of this study is to report 5 year disease control and toxicity. Methods: From May 2012 to February 2014, 18 women (stage IIA-IIIB) prospectively enrolled on a pilot study. Median age was 52 years (range, 42-73), with equal division between breast-conserving therapy (BCT) and mastectomy and right and left-sided cancers. Median number of positive nodes among the 16 node-positive patients was 2 (range, 1-14). Five patients had ≥ 10 nodes positive on axillary dissection (N3a). Treatment targets (CTVs for breast/chest wall, supraclavicular, axillary, internal mammary nodes (IMNs)) and organs at risk were delineated on CT scans. Double scatter PT alone was used for 10 patients (9 post-mastectomy, 1 after BCT) and combined proton-photon in 8 (all BCT). Toxicity was prospectively recorded using CTCAE v4.0. Results: Median follow-up was 4 years (range, 0.3 – 6). 5 year overall survival was 82% and locoregional control was 100%. 5 year distant metastases-free survival was 82%. No grade 4+ toxicity developed. Four patients developed grade 3 cellulitis, which was the only grade 3 toxicity. One patient had a reconstructive failure associated with a post-surgical cellulitis. A right-sided patient was diagnosed with CHF within 2 months of completion of PT, following diagnosis of a pulmonary embolus 1 month prior. She had an elevated BNP (1101) prior to PT following adriamycin-based chemotherapy. Mean heart dose was 0 Gy and cardiac V5 0%. Atrial fibrillation developed in two patients. One patient developed grade 2 pneumonitis (she received concurrent chemotherapy). One patient, with a history of rib fractures prior to PT, developed an ipsilateral rib fracture 7 months after PT. Conclusion: In a population of women with locally advanced breast cancer, PT for RNI has proven feasible after either mastectomy (with or without reconstruction) or BCT with excellent locoregional control. PT allows for highly conformal radiation delivery without compromise of target coverage or excess exposure of normal tissue. Documentation of the ultimate benefits of PT in this population, freedom from radiation induced cardiac disease and breast cancer recurrence will require prospective study of a larger numbers of patients. Citation Format: Bradley JA, Dagan R, Liang X, Ho MW, Rutenberg M, Mailhot R, Morris C, Mendenhall NP. Five year outcomes of a prospective study of proton radiotherapy for breast cancer regional nodal irradiation [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-16.
Abstract 650: An isogenic experimental model identifies β-catenin as a molecular target in ovarian cancer metastasis
Authors: Sally KY To, Alice ST Wong.
Journal: Cancer Research (2016)

Abstract Ovarian cancer metastasis is closely associated with unfavorable outcomes, yet the underlying mechanisms remain obscure. Here we establish an isogenic model that could mimic the spontaneous metastasis of human ovarian cancer. Given that tumor cells are heterogeneous in nature, an isogenic pair of highly metastatic (HM) and non-metastatic (NM) cell lines with opposite metastatic capabilities was derived using in vitro and in vivo selection. Incorporation of the luciferase gene into the cell pair allowed non-invasive monitoring of the metastatic events by bioluminescent imaging in vivo. Orthotopic implantation of HM into the ovarian bursa of NOD/SCID mice resulted in metastases within the peritoneum with ascites formation, thus representing the major dissemination pattern of human ovarian cancer cells. However, NM failed to form detectable metastases, although it was tumorigenic at the ovarian bursa. In comparison with NM, HM displayed higher spheroid-forming ability and had higher expression of stemness marker genes, which are characteristics of cancer stem-like population. By proteomic profiling and pathway analysis, HM is found to be enriched in the oncogenic β-catenin signaling, a pathway elevated in ovarian cancer metastases. Tumor initiation and metastasis of HM was dramatically impaired when β-catenin was specifically knocked down. We further demonstrated that β-catenin could down-regulate the expression of Dicer, a major component of the microRNA machinery. These results together suggest that this model could help to delineate the molecular mechanisms for ovarian cancer metastasis, and provide clinically relevant insights to target metastasizing ovarian cancer cells. Citation Format: Sally KY To, Alice ST Wong. An isogenic experimental model identifies β-catenin as a molecular target in ovarian cancer metastasis. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 650.
'CLIP WITH LINE' TECHNIQUE FOR SUCCESSFUL LUXATION OF THE PAPILLARY ORIFICE FROM A DUODENAL DIVERTICULUM AND SUCCESSFUL CANNULATION
Authors: A Horn, V Meves, J Hochberger
Journal: Endoscopy (2019)

Duodenal diverticula (DD) are a frequent condition (approximately 10 – 20% of all patients). An endoscopic retrograde cholangioscopy (ERC) of those patients can be challenging. We report a patient with a large DD. The papilla vateri (PV) is located completely in the diverticulum. The initial cannulation of the bile duct orifice (BDO) was difficult. This video shows a possibility to make the cannulation and the sphincterotomy feasible in cases with a DD. Transferred from Endoscopic Submucosa Dissection, we used the 'Clip with Line' technique for the first time in an ERC to cannulate the intra-diverticular site of the papillary orifice.